Antineoplastics
1
Reactions 885 - 19 Jan 2002 S Antineoplastics Acute myeloid leukaemia: case report A 45-year-old woman developed CD7 + acute myeloid leukaemia with trisomy 8 after she received antineoplastic therapy for acute myelomonocytic leukaemia. The woman received induction therapy with enocitabine [behenoyl cytarabine], daunorubicin, mercaptopurine and prednisolone [dosages and duration of treatment not stated] and achieved complete remission. She then received 4 courses of consolidation antineoplastic therapy, as for induction therapy, and had no evidence of residual disease. Overall, she received a total cumulative enocitabine dose of 7000 mg/m 2 , 750 mg/m 2 of daunorubicin and 2450 mg/m 2 of mercaptopurine. Four years later, the woman developed leucopenia and thrombocytopenia. A bone marrow aspirate showed hypocellular marrow. The blast cells showed a myeloid feature, trisomy 8 and CD7 antigen. She was diagnosed with therapy-related hypoplastic myeloid leukaemia and treated with low-dose cytarabine. Three months later, the blast cells of her peripheral blood had increased to 85%. She died as a result of pneumonia 4 months after acute myeloid leukaemia was diagnosed. Author comment: ‘Therapy-related acute myeloid leukemia (t-AML) has been described with an increased frequency following primary malignancies.’ Tanaka M, et al. Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia. Anti-Cancer Drugs 12: 681-682, Sep 2001 - Japan 800880560 1 Reactions 19 Jan 2002 No. 885 0114-9954/10/0885-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 885 - 19 Jan 2002
SAntineoplastics
Acute myeloid leukaemia: case reportA 45-year-old woman developed CD7+ acute myeloid
leukaemia with trisomy 8 after she received antineoplastictherapy for acute myelomonocytic leukaemia.
The woman received induction therapy with enocitabine[behenoyl cytarabine], daunorubicin, mercaptopurine andprednisolone [dosages and duration of treatment not stated]and achieved complete remission. She then received 4 coursesof consolidation antineoplastic therapy, as for inductiontherapy, and had no evidence of residual disease. Overall, shereceived a total cumulative enocitabine dose of 7000 mg/m2,750 mg/m2 of daunorubicin and 2450 mg/m2 ofmercaptopurine.
Four years later, the woman developed leucopenia andthrombocytopenia. A bone marrow aspirate showedhypocellular marrow. The blast cells showed a myeloidfeature, trisomy 8 and CD7 antigen. She was diagnosed withtherapy-related hypoplastic myeloid leukaemia and treatedwith low-dose cytarabine. Three months later, the blast cells ofher peripheral blood had increased to 85%. She died as a resultof pneumonia 4 months after acute myeloid leukaemia wasdiagnosed.
Author comment: ‘Therapy-related acute myeloid leukemia(t-AML) has been described with an increased frequencyfollowing primary malignancies.’Tanaka M, et al. Therapy-related CD7+ acute myeloid leukemia with trisomy 8following acute monocytic leukemia. Anti-Cancer Drugs 12: 681-682, Sep 2001 -Japan 800880560
1
Reactions 19 Jan 2002 No. 8850114-9954/10/0885-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
